Scannell, Jack W. http://orcid.org/0000-0002-0480-4140
Bosley, James
Hickman, John A. http://orcid.org/0000-0002-6661-8175
Dawson, Gerard R. http://orcid.org/0000-0002-8624-7500
Truebel, Hubert http://orcid.org/0000-0001-6413-7864
Ferreira, Guilherme S. http://orcid.org/0000-0001-5606-6525
Richards, Duncan http://orcid.org/0000-0002-8093-7084
Treherne, J. Mark http://orcid.org/0000-0001-6667-3118
Article History
Accepted: 11 August 2022
First Online: 4 October 2022
Competing interests
: J.W.S. is a director and shareholder of JW Scannell Analytics, which sells consulting services to the biopharmaceutical and financial services sectors, including to firms that are commercializing screening and disease models; is CEO of Unify Pharmaceuticals Corp; is Director of Etheros Pharmaceuticals Corp; and holds equity options in Ochre Bio. J.B. is an employee of Novadiscovery and holds equity options in the firm. G.R.D. is a director and major shareholder of P1vital and P1vital Products Ltd. P1vital provides clinical research services to the pharmaceutical industry. P1vital Products provides data management and digital technology to the pharmaceutical industry and health-care providers. H.T. is employed by AiCuris AG, owns shares in Bayer AG, Evotec SE, Cyclerion Therapeutics, Inc. and recently incorporatedExternalRef removed. G.S.F. has received fees from Merck KGaA and Curare Consulting; has been employed by the Access to Medicine Foundation, 3D PharmXchange and Janssen Biologics; and is now employed by GlaxoSmithKline. D.R. is a consultant to OMASS Therapeutics Ltd and is on the scientific advisory board of Avicenna Biosciences, Inc. J.M.T. is a director and/or shareholder of Talisman Therapeutics, Gen2 Neuroscience, Avilex Pharma, Domain Therapeutics, Cellesce, Ubiquigent and Monument Therapeutics. J.A.H. declares no competing interests.